Karen F.
- Country
- Belgium
- Department
- Urology
Research Overview
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676)
Data & Insights
Has run more than one trial at 12 of 114 partner sites.
Specializations
Bladder Cancer Research
The investigator specializes in treating non-muscle invasive bladder cancer, with particular emphasis on both high-risk and intermediate-risk cases. Their research encompasses innovative therapeutic approaches for patients with specific genetic markers.
- FGFR-positive bladder cancer treatment
- Intravesical therapy applications
- High-risk bladder cancer management
Their expertise extends to personalized treatment strategies based on genetic alterations in bladder cancer.
Immunotherapy Focus
The investigator explores novel immunotherapeutic approaches in bladder cancer treatment, particularly studying the effectiveness of combining immunotherapy with traditional treatments.
- BCG immunotherapy optimization
- Combination therapy development
- Treatment response assessment
Their work includes evaluation of maintenance therapy protocols and their impact on treatment outcomes.
Treatment Outcomes
The investigator focuses on measuring and improving key clinical outcomes in bladder cancer therapy, including disease-free survival and complete response rates.
- Clinical response evaluation
- Event-free survival analysis
- Treatment effectiveness markers
Their research emphasizes comparative therapeutic approaches to optimize treatment selection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.